# Study Evaluating Multiple Ascending Doses Of ATN-103 In Japanese Subjects With Rheumatoid Arthritis

> **NCT01007175** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ablynx, a Sanofi company** · enrollment: 60 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** ATN-103 10 mg q4wks
- **BIOLOGICAL:** ATN-103 30 mg q4wks
- **BIOLOGICAL:** ATN-103 80 mg q4wks
- **BIOLOGICAL:** ATN-103 10 mg q8wks
- **BIOLOGICAL:** ATN-103 80 mg q8wks

## Key facts

- **NCT ID:** NCT01007175
- **Lead sponsor:** Ablynx, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2013-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01007175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01007175, "Study Evaluating Multiple Ascending Doses Of ATN-103 In Japanese Subjects With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01007175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*